PubMedCrossRef 4 Broderick P, Carvajal-Carmona L, Pittman AM, We

PubMedCrossRef 4. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, et Stem Cells inhibitor al.: A genome-wide association study shows that common alleles of SMAD7 influence ubiquitin-Proteasome degradation colorectal cancer risk. Nat Genet 2007, 39:1315–1317.PubMedCrossRef 5. Tenesa A, Dunlop MG: New insights into the aetiology

of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009, 10:353–358.PubMedCrossRef 6. Pasche B, Luo Y, Rao PH, Nimer SD, Dmitrovsky E, Caron P, Luzzatto L, Offit K, Cordon-Cardo C, Renault B, Satagopan JM, Murty VV: Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res 1998, 58:2727–2732.PubMed 7. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, Massagué J, Offit K: T beta R-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999, 59:5678–5682.PubMed

8. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, Dolan ME, Vokes EE, Lane WS, Huang CC, Caldes T, Di Cristofano A, Hampel H, Nilsson I, von Heijne G, Fodde R, Murty VV, de la Chapelle A, Weghorst CM: Somatic Acquisition and Signaling of TGFBR1*6A in Cancer. JAMA: The Journal of the American Medical Association 2005, 294:1634–1646.CrossRef 9. Zhang HT, Zhao J, Zheng SY, Chen XF: Is TGFBR1*6A Really Associated With Increased Risk of Cancer? J Clin Oncol 2005, 23:7743–7744.PubMedCrossRef 10. Pasche B, Kaklamani not VG, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss buy Adavosertib M, Zheng T: TGFBR1*6A and Cancer: A Meta-Analysis of 12 Case-Control Studies. J Clin Oncol 2004, 22:756–758.PubMedCrossRef 11. Skoglund y, Song B, Dalen J, Dedorson S, Edler D, Hjern F, Holm J, Lenander C, Lindforss U, Lundqvist N, Olivecrona H, Olsson L, Påhlman L, Rutegård J, Smedh K, Törnqvist A, Houlston RS, Lindblom A: Lack of an Association between the TGFBR1*6A Variant and Colorectal Cancer Risk. Clinical Cancer Research 2007, 13:3748–3752.PubMedCrossRef 12. Zeng Q, Phukan S,

Xu Y, Sadim M, Rosman DS, Pennison M, Liao J, Yang GY, Huang CC, Valle L, Di Cristofano A, de la Chapelle A, Pasche B: Tgfbr1 Haploinsufficiency Is a Potent Modifier of Colorectal Cancer Development. Cancer Res 2009, 69:678–686.PubMedCrossRef 13. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336–1338.PubMedCrossRef 14. Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM, de la Chapelle A: Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science 2008, 321:1361–1365.PubMedCrossRef 15.

Comments are closed.